<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9ECFC591-7C9D-49B7-9F6E-18FAD2D94172"><gtr:id>9ECFC591-7C9D-49B7-9F6E-18FAD2D94172</gtr:id><gtr:name>University of Lyon</gtr:name><gtr:address><gtr:line1>Caserne Sergent Blandan</gtr:line1><gtr:line2>37 Rue du Repos</gtr:line2><gtr:line3>69365</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D317E8C1-3E16-4E48-8AAC-E2A0961F5299"><gtr:id>D317E8C1-3E16-4E48-8AAC-E2A0961F5299</gtr:id><gtr:name>Erasmus University Medical Center</gtr:name><gtr:address><gtr:line1>PO Box 2040</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9ECFC591-7C9D-49B7-9F6E-18FAD2D94172"><gtr:id>9ECFC591-7C9D-49B7-9F6E-18FAD2D94172</gtr:id><gtr:name>University of Lyon</gtr:name><gtr:address><gtr:line1>Caserne Sergent Blandan</gtr:line1><gtr:line2>37 Rue du Repos</gtr:line2><gtr:line3>69365</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CB94DE9D-DB74-4C72-A90F-1F24C2EAAEE2"><gtr:id>CB94DE9D-DB74-4C72-A90F-1F24C2EAAEE2</gtr:id><gtr:firstName>Leon</gtr:firstName><gtr:surname>Aarons</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_G1100157"><gtr:id>DE7C54DB-EAB1-4403-BC91-C2ADAB9F8E6A</gtr:id><gtr:title>Rare disease use of clinical trial simulation for the chioce and optimization of study designs/Priomedchild Call/ER</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_G1100157</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Background: Rare diseases are defined based on their low incidence, less than one in 2,000. Whereas randomized controlled trials (RCTs) are currently the gold standard for drug evaluation, there is still no general validated approach for the assessment of (orphan) drugs in this field.|Objectives of the CRESim (Child-Rare-Euro-Simulation) project: To develop a platform performing trial modelling and simulation in order to identify optimal trial designs in children for the evaluation of (orphan) drugs tailored to different types of rare diseases.|Methods: In silico approach using RCT modelling and Monte Carlo simulation, implemented for different categories of rare diseases in pediatrics. Several RCTs with different experimental designs will be modelled and simulated, and the different designs will be compared in terms of trial duration and precision of the estimation of the treatment effect.|Expected Outcomes: Improvement and optimization of the development of new orphan drugs.|Dissemination of results: Dissemination will target those involved in drug development (i.e pharmacologists, therapeutic specialists, methodologists and statisticians), and in drug registration (public health decision makers), and registration authorities (EMEA and national agencies).</gtr:technicalSummary><gtr:fund><gtr:end>2014-08-14</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>196901</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Lyon</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Department of Clinical Pharmacology</gtr:department><gtr:description>Dravet Syndrome</gtr:description><gtr:id>FB8B2036-653B-4222-BD37-6A04DA8A1932</gtr:id><gtr:impact>A minimal PKPK model for clobazam, stiripentol and valproate.</gtr:impact><gtr:outcomeId>L7H6kc5JaEv-1</gtr:outcomeId><gtr:partnerContribution>They have reviewed the model with some imputs into the structural model</gtr:partnerContribution><gtr:piContribution>Jointly we have developed a minimum PBPK to desribe the PK of clobazam, stiripentol and valproate</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Lyon</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Department of Clinical Pharmacology</gtr:department><gtr:description>Lymphoma</gtr:description><gtr:id>C9AAFECE-8A39-49B2-919E-5AB9CF20ED54</gtr:id><gtr:impact>A minimal PBPK model for Methotrexate and Mercaptopurine</gtr:impact><gtr:outcomeId>CYiYizwZ4XB-1</gtr:outcomeId><gtr:partnerContribution>Feedback on the structural model</gtr:partnerContribution><gtr:piContribution>A framework for the development of minimal PBPK model for methotrexate and mercaptopurine</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Erasmus University Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Cystic Fibrosis</gtr:description><gtr:id>78746D0B-6A30-47D1-A283-88C6416B752A</gtr:id><gtr:impact>KPD model for DNAse alpha</gtr:impact><gtr:outcomeId>VENLDUWVW5U-1</gtr:outcomeId><gtr:partnerContribution>They performed the literature revied and provided some data for model validation.</gtr:partnerContribution><gtr:piContribution>Jointly we have developed a KPD model for DNase alpha.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>IMI</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>31399939-402B-4EC0-94EE-6828536AB94E</gtr:id><gtr:outcomeId>DGVVD8GRJD3</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>04D20431-62F5-4CFD-90CB-F34D1B2CE2B1</gtr:id><gtr:title>Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9797aedb1b39d92f171b221741df9b73"><gtr:id>9797aedb1b39d92f171b221741df9b73</gtr:id><gtr:otherNames>Ogungbenro K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>58a189f1edd006.93855721</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA1ACF0E-A6E4-4912-8816-7120880CF137</gtr:id><gtr:title>Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate.</gtr:title><gtr:parentPublicationTitle>Journal of pharmacokinetics and pharmacodynamics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9797aedb1b39d92f171b221741df9b73"><gtr:id>9797aedb1b39d92f171b221741df9b73</gtr:id><gtr:otherNames>Ogungbenro K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1567-567X</gtr:issn><gtr:outcomeId>5460cc738e68e1.98970645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05D31290-69AA-49BE-B10E-6191D7EC25AA</gtr:id><gtr:title>Experimental designs for small randomised clinical trials: an algorithm for choice.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2b9917204df1f1f8af0d4a976955045"><gtr:id>b2b9917204df1f1f8af0d4a976955045</gtr:id><gtr:otherNames>Cornu C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>5460cc731d6d88.42575369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4ED4E023-2293-457C-A06B-A4FE352F33B9</gtr:id><gtr:title>Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.</gtr:title><gtr:parentPublicationTitle>Journal of pharmacokinetics and pharmacodynamics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9797aedb1b39d92f171b221741df9b73"><gtr:id>9797aedb1b39d92f171b221741df9b73</gtr:id><gtr:otherNames>Ogungbenro K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1567-567X</gtr:issn><gtr:outcomeId>5460cc73b10ff1.97543659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88A02487-04D8-486F-803C-065620C77556</gtr:id><gtr:title>A physiologically based pharmacokinetic model for Valproic acid in adults and children.</gtr:title><gtr:parentPublicationTitle>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9797aedb1b39d92f171b221741df9b73"><gtr:id>9797aedb1b39d92f171b221741df9b73</gtr:id><gtr:otherNames>Ogungbenro K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0928-0987</gtr:issn><gtr:outcomeId>5460cc73d8c445.86717293</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C948F672-28C9-491C-966A-626BEF375123</gtr:id><gtr:title>A physiologically based pharmacokinetic model for clobazam and stiripentol in adults and children.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9797aedb1b39d92f171b221741df9b73"><gtr:id>9797aedb1b39d92f171b221741df9b73</gtr:id><gtr:otherNames>Ogungbenro K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0724-8741</gtr:issn><gtr:outcomeId>5460cc74091947.50089408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD5710B8-560E-4E68-B32E-4AA03E0C4852</gtr:id><gtr:title>Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients.</gtr:title><gtr:parentPublicationTitle>Mathematical medicine and biology : a journal of the IMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f68212efd4f87fddcef0565a80bb4d69"><gtr:id>f68212efd4f87fddcef0565a80bb4d69</gtr:id><gtr:otherNames>Eymard N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1477-8599</gtr:issn><gtr:outcomeId>58a189ee061517.26756962</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_G1100157</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>